The Experts below are selected from a list of 1263 Experts worldwide ranked by ideXlab platform
Purushottam B Jaju - One of the best experts on this subject based on the ideXlab platform.
-
effectiveness and safety of Isoxsuprine hydrochloride as tocolytic agent in arresting active threatened preterm labor and its role in maintenance tocolysis a prospective open label study
American Journal of Perinatology, 2019Co-Authors: Purushottam B JajuAbstract:Objective The aim of the study is to obtain insights on the short and long-term safety and effectiveness of Isoxsuprine hydrochloride as a tocolytic agent in the management of PTL. Study Design In this prospective, single-center, noncomparative study, patients (with preterm labor at gestational age of 24–37 weeks) were administered intravenous (IV) infusion of 40-mg Isoxsuprine hydrochloride until uterine quiescence, followed by intramuscular (IM) injection of Isoxsuprine hydrochloride 10 mg/4-hourly for first 24 hours and maintained with retard 40-mg sustained release capsule (two times a day) till the time of delivery or 37 completed weeks of pregnancy. Results All patients (n = 50) achieved successful tocolysis in 24 hours and 48 hours postadministration of Isoxsuprine hydrochloride (IV/IM/oral). Mean (±SD) gestation age at the time of delivery was 39.8 ± 2.1 weeks, with latency period of 58.5 ± 18.7 days. Pregnancy outcomes were normal in all the patients and no congenital anomaly/fetal infection was reported. Mean (±SD) fetal birth weight was 2.7 ± 0.3 kg; mean (±SD) Apgar score at 1 and 5 minutes were 7.5 ± 0.6 and 9.2 ± 0.4, respectively. Maternal tachycardia and vomiting (8.0% each) were the commonly reported adverse drug reactions, which were resolved with dose adjustment. Conclusion Isoxsuprine was found to be an effective and well-tolerated tocolytic agent in arresting PTL, in turn resulting in the overall improvement in maternal and perinatal outcomes.
Gary A Rosenberg - One of the best experts on this subject based on the ideXlab platform.
-
identification of Isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell based high throughput screening
PLOS ONE, 2014Co-Authors: Jeff W Hill, Jeffrey Thompson, Mark B Carter, Bruce S Edwards, Larry A Sklar, Gary A RosenbergAbstract:Stroke is a leading cause of death and disability and treatment options are limited. A promising approach to accelerate the development of new therapeutics is the use of high-throughput screening of chemical libraries. Using a cell-based high-throughput oxygen-glucose deprivation (OGD) model, we evaluated 1,200 small molecules for repurposed application in stroke therapy. Isoxsuprine hydrochloride was identified as a potent neuroprotective compound in primary neurons exposed to OGD. Isoxsuprine, a β2-adrenergic agonist and NR2B subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonist, demonstrated no loss of efficacy when administered up to an hour after reoxygenation in an in vitro stroke model. In an animal model of transient focal ischemia, Isoxsuprine significantly reduced infarct volume compared to vehicle (137±18 mm3 versus 279±25 mm3, p<0.001). Isoxsuprine, a peripheral vasodilator, was FDA approved for the treatment of cerebrovascular insufficiency and peripheral vascular disease. Our demonstration of the significant and novel neuroprotective action of Isoxsuprine hydrochloride in an in vivo stroke model and its history of human use suggest that Isoxsuprine may be an ideal candidate for further investigation as a potential stroke therapeutic.
-
Identification of Isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening.
PLoS ONE, 2014Co-Authors: Jeff W Hill, Jeffrey Thompson, Mark B Carter, Bruce S Edwards, Larry A Sklar, Gary A RosenbergAbstract:Stroke is a leading cause of death and disability and treatment options are limited. A promising approach to accelerate the development of new therapeutics is the use of high-throughput screening of chemical libraries. Using a cell-based high-throughput oxygen-glucose deprivation (OGD) model, we evaluated 1,200 small molecules for repurposed application in stroke therapy. Isoxsuprine hydrochloride was identified as a potent neuroprotective compound in primary neurons exposed to OGD. Isoxsuprine, a β2-adrenergic agonist and NR2B subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonist, demonstrated no loss of efficacy when administered up to an hour after reoxygenation in an in vitro stroke model. In an animal model of transient focal ischemia, Isoxsuprine significantly reduced infarct volume compared to vehicle (137±18 mm3 versus 279±25 mm3, p
Colin Gerard Egan - One of the best experts on this subject based on the ideXlab platform.
-
Use of Isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature.
Arzneimittelforschung, 2011Co-Authors: Francesco Libero Giorgino, Colin Gerard EganAbstract:The aim of this systematic review was to evaluate the efficacy of Isoxsuprine (1-(4-hydroxyphenyl)-2-(1-methyl-2-phe-noxyethylamino)-1-propanol, CAS 395-28-8), a tocolytic agent used in both preterm labour and risk of abortion. Two analyses were conducted on data reporting the use of Isoxsuprine in the prevention of preterm delivery. The first analysis examined two double-blind studies to determine the effect of Isoxsuprine compared to placebo. The second analysis reviewed data from 25 publications containing individual and general patient data. Main outcome measures included delay of pregnancy and patient outcome. Analysis of double-blind studies demonstrated a positive outcome with Isoxsuprine in 92% of cases compared to placebo control (44.4%, p < 0.001). This beneficial effect was maintained when either risk of abortion (92.5% in Isoxsuprine treated compared to 46.4% in placebo, p < 0.001) or risk of premature delivery (89.5% in Isoxsuprine treated compared to 29.4% in placebo, p < 0.001) was examined. Secondary analysis of individual patient data also revealed a beneficial effect of Isoxsuprine in prolonging pregnancy in 54.5% of women at risk of abortion and in 82.3% of women at risk of premature delivery. Combination of individual and general data revealed a beneficial effect of Isoxsuprine in 77.3% of cases at risk of abortion and 89% for risk of premature delivery. These findings provide preliminary evidence in favour of the effectiveness of Isoxsuprine in prolonging pregnancy in women at risk of abortion or premature delivery.
-
Use of Isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature.
Drug Research, 2011Co-Authors: Francesco Libero Giorgino, Colin Gerard EganAbstract:The aim of this systematic review was to evaluate the efficacy of Isoxsuprine (1-(4-hydroxyphenyl)-2-(1-methyl-2-phenoxyethylamino)-1-propanol, CAS 395-28-8), a tocolytic agent used in both preterm labour and risk of abortion. Two analyses were conducted on data reporting the use of Isoxsuprine in the prevention of preterm delivery. The first analysis examined two double-blind studies to determine the effect of Isoxsuprine compared to placebo. The second analysis reviewed data from 25 publications containing individual and general patient data. Main outcome measures included delay of pregnancy and patient outcome. Analysis of double-blind studies demonstrated a positive outcome with Isoxsuprine in 92% of cases compared to placebo control (44.4%, p These findings provide preliminary evidence in favour of the effectiveness of Isoxsuprine in prolonging pregnancy in women at risk of abortion or premature delivery.
Britt-ingjerd Nesheim - One of the best experts on this subject based on the ideXlab platform.
-
Action of Tsoprenaline, Isoxsuprine and Ritodrine in the Human Non–pregnant Myometrium
Pharmacology & Toxicology, 2009Co-Authors: P. Berg–johnsen, Britt-ingjerd NesheimAbstract:The effects of isoprenaline, Isoxsuprine and ritodrine were tested on spontaneously contracting muscle strips from non–pregnant human uterus in vitro. The strips were rather insensitive to all three drugs, the maximal inhibitions obtained being: Isoxsuprine (10–4 M) 81 %, ritodrine (10–4 M) 45 %, isoprenaline (10–5 M) 19%. Propranolol 3.4 × 10–6 M did not significantly block the effects of Isoxsuprine and ritodrine. It is concluded that the non–pregnant human uterus is rather insentitive to β–adrenoceptor stimulation, and that Isoxsuprine and ritodrine act mainly through unspecific mechanisms.
-
action of tsoprenaline Isoxsuprine and ritodrine in the human non pregnant myometrium
Pharmacology & Toxicology, 2009Co-Authors: Berg P Johnsen, Britt-ingjerd NesheimAbstract:The effects of isoprenaline, Isoxsuprine and ritodrine were tested on spontaneously contracting muscle strips from non–pregnant human uterus in vitro. The strips were rather insensitive to all three drugs, the maximal inhibitions obtained being: Isoxsuprine (10–4 M) 81 %, ritodrine (10–4 M) 45 %, isoprenaline (10–5 M) 19%. Propranolol 3.4 × 10–6 M did not significantly block the effects of Isoxsuprine and ritodrine. It is concluded that the non–pregnant human uterus is rather insentitive to β–adrenoceptor stimulation, and that Isoxsuprine and ritodrine act mainly through unspecific mechanisms.
Jeff W Hill - One of the best experts on this subject based on the ideXlab platform.
-
identification of Isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell based high throughput screening
PLOS ONE, 2014Co-Authors: Jeff W Hill, Jeffrey Thompson, Mark B Carter, Bruce S Edwards, Larry A Sklar, Gary A RosenbergAbstract:Stroke is a leading cause of death and disability and treatment options are limited. A promising approach to accelerate the development of new therapeutics is the use of high-throughput screening of chemical libraries. Using a cell-based high-throughput oxygen-glucose deprivation (OGD) model, we evaluated 1,200 small molecules for repurposed application in stroke therapy. Isoxsuprine hydrochloride was identified as a potent neuroprotective compound in primary neurons exposed to OGD. Isoxsuprine, a β2-adrenergic agonist and NR2B subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonist, demonstrated no loss of efficacy when administered up to an hour after reoxygenation in an in vitro stroke model. In an animal model of transient focal ischemia, Isoxsuprine significantly reduced infarct volume compared to vehicle (137±18 mm3 versus 279±25 mm3, p<0.001). Isoxsuprine, a peripheral vasodilator, was FDA approved for the treatment of cerebrovascular insufficiency and peripheral vascular disease. Our demonstration of the significant and novel neuroprotective action of Isoxsuprine hydrochloride in an in vivo stroke model and its history of human use suggest that Isoxsuprine may be an ideal candidate for further investigation as a potential stroke therapeutic.
-
Identification of Isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening.
PLoS ONE, 2014Co-Authors: Jeff W Hill, Jeffrey Thompson, Mark B Carter, Bruce S Edwards, Larry A Sklar, Gary A RosenbergAbstract:Stroke is a leading cause of death and disability and treatment options are limited. A promising approach to accelerate the development of new therapeutics is the use of high-throughput screening of chemical libraries. Using a cell-based high-throughput oxygen-glucose deprivation (OGD) model, we evaluated 1,200 small molecules for repurposed application in stroke therapy. Isoxsuprine hydrochloride was identified as a potent neuroprotective compound in primary neurons exposed to OGD. Isoxsuprine, a β2-adrenergic agonist and NR2B subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonist, demonstrated no loss of efficacy when administered up to an hour after reoxygenation in an in vitro stroke model. In an animal model of transient focal ischemia, Isoxsuprine significantly reduced infarct volume compared to vehicle (137±18 mm3 versus 279±25 mm3, p
